Table 1.
Factors | Source | Sample | Sample size | Cut-off value or characterization | Time of measurement | Prognostic role |
H. pylori | Germany | Sera | 166 | Positivity | Prior to gastrectomy | Increased OS and RFS[17] |
H. pylori | China | Tumor tissue | 162 | Positivity | At the time of surgery | Decreased OS and RFS[18] |
H. pylori | Brazil | Tumor tissue | 68 | Positivity | At the time of surgery | No difference[19] |
H. pylori | South Korea | Sera | 274 | Negativity | At the time of surgery and adjuvant chemotherapy | Decreased OS[20] |
H. pylori | Italy | Sera and tumor tissue | 297 | Negativity | At the time of surgery | Decreased OS[21] |
H. pylori | Brazilian, Asian and Caucasian | Sera | 2454 | Positivity | At the time of surgery | Increased OS and DFS[22] |
EBV | Taiwan | Sera | 150 | Positivity | Prior to gastrectomy | Increased OS[27] |
EBV | Korea | Sera | 123 | Expression | At the time of surgery | Increased OS and DFS[28] |
EBV | Asia, Europe and Latin America | Sera | 4599 | Positivity | At the time of surgery | Increased OS[29] |
DFS: Disease-free survival; EBV: Epstein-Barr virus; H. pylori: Helicobacter pylori; OS: Overall survival; RFS: Relapse-free survival.